Evidence map›Paper›PMID 19948376›Full record

ArticleCancer letters2010

Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.

Michael R Garbati, Gökçen Alço, Thomas D Gilmore

Open access · greenAbstract read
In one paragraph

Article in Cancer letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Epigenetics and B-cell lymphoma.Current opinion in hematology · 2011
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael R GarbatiDepartment of Biology, Boston University, Boston, MA 02215, USA.
Gökçen Alço
Thomas D Gilmore
Boston University · US

Funding

TRANSFORMATION OF CELLS BY THE V-REL ONCOGENER01CA047763 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILMORE, THOMAS DAVID · 1993 to 2009
$2.7M
TRANSFORMATION OF CELLS BY THE V-REL ONCOGENER29CA047763 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILMORE, THOMAS DAVID · 1988 to 1992
–
NCI NIH HHS CA047763NCI NIH HHS CA047763-21S3NCI NIH HHS R01 CA047763
6 · The paper itself

Abstract

Human c-Rel (REL) is a member of the NF-kappaB family of transcription factors. REL's normal physiological role is in the regulation of B-cell proliferation and survival. The REL gene is amplified in many human B-cell lymphomas and overexpression of REL can transform chicken lymphoid cells. In this report, histone acetyltransferase p300 enhanced REL-induced transactivation and interacted with REL both in vitro and in REL-transformed chicken spleen cells and the B-lymphoma cell line RC-K8, in which REL is constitutively active and required for proliferation. However, due to a deletion in the EP300 locus, only a C-terminally truncated form of p300 is expressed in RC-K8 cells. These results suggest a role for p300 in REL-mediated oncogenic activity in B lymphoma.

Indexed as

AnimalsCell Line, TumorCells, CulturedCell Transformation, NeoplasticChickensGenes, ReporterGlutathione TransferaseHistone AcetyltransferasesHumansKidneyLuciferasesLymphoma, B-CellLymphoma, Large B-Cell, DiffuseNF-kappa BPolymerase Chain ReactionProto-Oncogene Proteins c-relGlutathione TransferaseHistone AcetyltransferasesLuciferasesNF-kappa BProto-Oncogene Proteins c-relRecombinant Fusion Proteins

Identifiers

PMID19948376
PMCPMC2849871
OpenAlexW2116855217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.